A case report highlights the successful management of suspected Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a patient with BRAF-mutant cholangiocarcinoma. The treatment involved immune checkpoint inhibitors and BRAF/MEK inhibitors, showcasing potential therapeutic strategies for this rare condition.
successful management of suspected epstein barr virus associated hemophagocytic lymphohistiocytosis in braf mutant cholangiocarcinoma following treatment with immune checkpoint inhibitors and braf mek inhibitors a case report
Original title: “Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report.”